Table 3.

Efficacy of hybridoma antibodies against intranasal LVS infection of BALB/c mice

LVS inoculation/Ab treatmenta	No. of surviving mice/total	Mean time to death ± SD (days)	Median survival (days)	p value of log rank test
Experiment 1
4×104 CFU i.n./100 μg i.p.				versus isotype control
3 (G2a)	2/5	13.7 ± 2.5	16	0.003
9 (G1)	0/5	13.8 ± 4.7	16	0.033
2 (G3)	0/5	9.4 ± 1.5	9	0.011
7 (M)	0/5	8.2 ± 1.3	8	0.333
7 (M)/600 μg	0/5	7.6 ± 0.9	7	0.918
CO17-1A (G control)	0/5	7.6 ± 0.5	8	NAb
19 (M control)	0/5	7.6 ± 0.5	8	NA
PBS	0/5	8.0 ± 0.0	8	NA
Experiment 2
2×104 CFU i.n./200 μg i.p.				versus Sp2/0
FB11 (G2a)	5/5	NA	undefinedc	0.003
3 (G2a)	5/5	NA	undefined	0.003
10 (G2a)	0/5	7.4 ± 1.5	7	0.133d
3+10 (G2a)	5/5	NA	undefined	0.003
11 (G2b)	0/5	10.6 ± 2.7	11	0.192
13+31 (G1)	0/5	7.4 ± 1.5	7	0.044d
12 (G3)	1/5	12.0 ± 6.6	13	0.206
10+11+13+31 (G)	0/5	10.2 ± 3.1	10	0.422
3+10+11+13+31 (G)	5/5	NA	undefined	0.003
Sp2/0 (fusion partner)	0/5	9.2 ± 1.3	10	NA
Experiment 3A
2×104 CFU i.n./50 μg i.n.				versus isotype control
3 (G2a)	5/5	NA	undefined	0.001
CO17-1A (G2a)	0/5	15.6 ± 5.9	17	NA
Experiment 3B
2×105 CFU i.n./50 μg i.n.				versus isotype control
3 (G2a)	3/5	16.0 ± 0.0	undefined	0.003
CO17-1A (G2a)	0/5	7.8 ± 1.6	9	NA

^aMice were inoculated i.n. with the indicated number of LVS CFU, then treated i.p. (1 h later) or i.n. (within minutes) with supernatants containing the indicated Ab and dose or with PBS or Sp2/0 supernatant

^bNot applicable

^cSurvival exceeds 50% at the longest time point

^dThe p values are different for Ab10 and Ab13+Ab31 because of differences in the day of death of individual mice in these two groups compared to the day of death in the Sp2/0 control group